This inventor holds 1 USPTO granted patent. Top assignee: Pharmingen. Active years: 1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1999
Title: Bi-Ching Sang: Innovator in Monoclonal Antibody Development
Introduction
Bi-Ching Sang is a prominent inventor based in San Diego, CA. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. Her innovative work has led to the creation of a unique patent that addresses specific medical needs.
Latest Patents
Bi-Ching Sang holds a patent for the E2A/pbx1 fusion protein specific monoclonal antibodies. This monoclonal antibody is designed to specifically bind with an E2A/pbx1 fusion epitope, which has important implications for targeted therapies in cancer treatment. Her patent portfolio includes 1 patent that showcases her expertise in this specialized area.
Career Highlights
Bi-Ching Sang is currently employed at Pharmingen, a company known for its advancements in immunology and biotechnology. Her role at Pharmingen allows her to collaborate with other experts in the field and contribute to groundbreaking research and development.
Collaborations
Throughout her career, Bi-Ching Sang has worked alongside notable colleagues such as Stefan Gruenwald and Craig Monell. These collaborations have further enhanced her research and innovation capabilities, leading to significant advancements in monoclonal antibody technology.
Conclusion
Bi-Ching Sang's contributions to the field of biotechnology, particularly through her patent on monoclonal antibodies, highlight her role as an influential inventor. Her work continues to pave the way for advancements in targeted therapies, making a lasting impact on medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile